`
`2023-1164
`AstraZeneca AB v. Mylan Pharmaceuticals Inc.
`AstraZeneca AB; AstraZeneca Pharmaceuticals LP
`
`D. Ct. (N.D.W. Va.)
`
`18-cv-193; 19-cv-203
`
`Patent
`
`Reversal of the District Court's judgment.
`
`The District Court found the asserted claims of U.S. Patent No. 10,166,247 invalid
`for lack of enablement and lack of written description, pursuant to 35 U.S.C. § 112.
`
`As stated in the Notice of Appeal, Plaintiffs-Appellants appeal from the Final Judgment (ECF No. 607) and other "orders, decisions,
`rulings, findings, and conclusions underlying and related to that judgment," including the November 9, 2022 Memorandum Opinion and
`Order Following Bench Trial (ECF No. 606) and the March 22, 2022 Order Granting Defendants' Motion to Strike (ECF No. 521).
`
`11/9/22
`
`
`
`Case: 23-1164 Document: 11 Page: 2 Filed: 11/21/2022
`
`Whether the District Court's judgment should be reversed.
`
`N/A
`
`The parties' current positions preclude settlement.
`
`None.
`
`11/21/22
`
`/s/ David I. Berl
`David I. Berl
`
`